Texas (Mar. 28, 2013) Wax Ink has issued a Exploratory Investment Interest rating for Acordia Therapeutics, Inc. (Nasdaq: ACOR) based on a recent baseline equity review which placed fair value between $40-$53.
The recent close of $31.65 is approximately 33% above the fair value buy target for the stock and approximately 36% below the fair value close target for the stock. The recent close is also 2% above analysts' $31.00 median target for the stock.
The stock currently has a trailing twelve month PE Ratio of 8, and a PEG Ratio of 0.4 basis estimated forward earnings growth of 18%.
In the past 52 weeks, share prices have moved between a high of $31.73 and a low of $21.04. With the recent close, the stock is trading 0.3% below the 52 week high and 34% above the 52 week low.
Acordia Therapeutics, Inc. is a commercial stage biopharmaceutical company engaged in the identification, development and commercialization of therapies for multiple sclerosis and spinal cord injuries.
All valuations are based on the listed company's most recent SEC annual filing, and all prices are per share.
Wax Ink.net is a baseline equity research company comprised of individual investors, NOT licensed or registered with ANY government agency.
Copyright © 2013 Wax Ink
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.